Cerus Corporation
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000HBVZX8
CERS
Cerus Corporation
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Medical Devices
NAME
Cerus Corporation
ISIN
US1570851014
TICKER
CERS
MIC
XNAS
REUTERS
CERS.OQ
BLOOMBERG
CERS US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mi., 13.11.2024
Cerus
US1570851014
Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.
Management plans to participate in the Stifel 2024 Healthcare Conference on Monday, November 18th at 4:10 PM ET, and will attend the Craig-Hallum Alpha Select Conference on Tuesday, November 19th.
A live webcast of the Stifel 2024 Healthca...
Mi., 30.10.2024
Cerus
US1570851014
Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended September 30, 2024.
Total revenue for the three and nine months ended September 30, 2024 was comprised of (in thousands, except %):
Three Months Ended
Nine Months Ended
September 30,
Change
September...
Fr., 18.10.2024
Cerus
US1570851014
Cerus Corporation (Nasdaq: CERS) today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting, taking place in Houston, Texas from October 19 through October 22. This year’s AABB Annual Meeting attracts individuals and institutions from around the globe invol...
Fr., 18.10.2024
Cerus
US1570851014
Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2024 financial results will be released on Wednesday, October 30, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a g...
Mi., 16.10.2024
Cerus
US1570851014
Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe:
U.S. – New $248 million BARDA contract supports program beyond U.S. Phase 3 studies through anticipated PMA licensure and into commercialization
Europe – CE Mark review has been concluded without approval; assessing...
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
